InsidersTradesSigma
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Explore the full record of transactions filed by Douglas Earl Martin. Director active across 2 companies, notably Allogene Therapeutics, Inc.. Aggregated, 7 reports have been recorded. Split: 0 buy · 3 sells. Total volume traded: €99k. History available since 14 August 2023. The latest transaction was disclosed on 21 August 2026 (Cession). Regulator: SEC (Form 4). All data is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 条申报中的 7 条
Douglas Earl Martin is a declarant linked to Allogene Therapeutics, Inc. (XNAS), where he is SVP, General Counsel. He has 6 filings in total, and among the sampled recent filings, the period runs from 2023-08-17 to 2026-02-04, with EUR 0 of buys and EUR 44700 of sells; the stated transaction nature is Attribution.